- Home
- Software Solutions
- Resources
- Corporate
Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors
Sponsors:
| Phases:
| |
| Indications | Acronym: BEL | |
| ||
Age Groups:
| Gender: Both | |
Names:
| Enrollment: 100 | |
Additional information about NCT01055795.